Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus PROMETHEGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus PROMETHEGAN.
BENADRYL vs PROMETHEGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Promethazine is a phenothiazine derivative that acts as a competitive antagonist at histamine H1 receptors, exerting antihistaminic, sedative, antiemetic, anticholinergic, and local anesthetic effects. Its antiemetic effect is mediated via blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
IV: 25-50 mg every 4-6 hours; IM: 25-50 mg every 4-6 hours; PO: 25-50 mg every 4-6 hours; PR: 25-50 mg every 4-6 hours; Maximum: 300 mg/day.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life: 9-16 hours in adults, with an average of 12 hours. In children, half-life may be shorter (6-9 hours). Clinical context: dosing interval typically every 8-12 hours; accumulation possible with repeated dosing.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Primarily renal (urinary) as conjugated metabolites; about 70-80% of a dose is excreted in urine within 48 hours. Small amounts appear in feces via biliary elimination (approximately 5-10%).
Category C
Category C
Antihistamine
Antihistamine